Validating literature-based models with direct clinical trial results: The cost-effectiveness of secondary prophylaxis for PCP in AIDS patients

Medical Decision Making

Volumn 16, Issue 1, 1996, Pages 29-35

  Freedberg, Kenneth A ^a,b,f   Hardy, W David ^c   Holzman, Robert S ^d   Tosteson, Anna N A ^e   Craven, Donald E ^b  

^a Clinical Economics Research Unit   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f BOSTON MEDICAL CENTER   (United States)

Author keywords

cost effectiveness; decision models; Pneumocystis carinii pneumonia

Indexed keywords

COTRIMOXAZOLE; PENTAMIDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE POLICY; HUMAN; INFECTION PREVENTION; INFECTION RISK; INHALATIONAL DRUG ADMINISTRATION; MEDICAL DECISION MAKING; PNEUMOCYSTIS PNEUMONIA; RANDOMIZED CONTROLLED TRIAL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MODELS, STATISTICAL; PENTAMIDINE; PNEUMONIA, PNEUMOCYSTIS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0030053150     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X9601600110     Document Type: Article

References (26)

1. 3: a cost-effectiveness analysis, J Acquir Immune Def Syn 1991,4:521-31.
2. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: estimates using decision analysis while awaiting clinical trial results. JAMA. 1992;2267:2055-61
3. Murray JK, Felton CP, Garay SM, et al. Pulmonary complications of the acquired immunodeficiency syndrome: report of a National Heart, Lung and Blood Institute workshop. N Engl J Med. 1984;310:1682-8.
4. Centers for Disease Control and Prevention Draft 1993 year-end HIV/AIDS Surveillance Report, March 29, 1994.
5. Fischl MA, Parker CB, Petinelli C, et al. A randomized trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1990;323:1009-14.
6. Leoung GS, Feigal DW, Montgomery AB, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia: the San Francisco community prophylaxis trial. N Engl J Med. 1990;323:769-75.
7. Hirschel B, Lazzarin A, Chopard P, et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia N Engl J Med. 1991;324:1079-83.
8. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 1988;259:1185-9.
9. Ruskin J, LaRiviere M Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease Lancet 1991;337:468-71
10. Kemper CA, Tucker RM, Lang OS, et al. Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. AIDS. 1990;4:1145-8
11. Hughes WT, Kennedy W, Dugdale M, et al. Prevention of Pneumocystis carinii pneumonia in AIDS patients with weekly dapsone [letter]. Lancet. 1990;336?:1066.
12. Freedberg KA, Craven DE. The cost-effectiveness of prophylaxis for recurrent Pneumocystis carinii pneumonia in AIDS patients [abstr]. Clin Res. 1991;39:587A.
13. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;327:1842-8.
14. Beck JR, Pauker SG The Markov process in medical prognosis. Med Decis Making 1983;3:419-58.
15. Fischl MA, Richman DD, Gricco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med. 1987;317:185-91
16. Redbook 1992. Oradell, New Jersey: Medical Economics, 1992.
17. Boston City Hospital, Boston MA. Office of payment, 1992.
18. Hellinger FJ The lifetime cost of treating a person with HIV. JAMA. 1993;270:474-8
19. Bennett CL, Bennett RL, Hintz E, Fahs MC, Arno P. Differences in costs of care among patients with AIDS-related Pneumocystis carinii pneumonia according to hospital type: results from a 10-city study [abstr] Veterans Administration Health Services Research and Development Annual Meeting, Washington, DC. 1994.
20. Weinstein MC, Stason WB Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716-21.
21. U.S. Public Health Service Task Force on Antipneumocystis Prophylaxis for Patients with Human Immunodeficiency Virus Infection. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. Centers for Disease Control. MMWR 1992;41-RR4:1-11
22. Castellano AR, Nettleman MD. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA. 1991;266:820-4.
23. Raviglione MC, Nash EN, Cortes H, Mariuz P, Sanjana V. Intermittent co-trimoxazole prophylaxis against Pneumocystis carinii pneumonia [letter] Lancet 1990;336?:180.
24. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993,328:1521-7.
25. Paltiel AD, Kaplan EH The epidemiological and economic consequences of AIDS clinical trials J Acquir Immune Def Syn. 1993;6:179-90.
26. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst. 1993;85:1460-74.